Mettler-Toledo International Stock Testing Price Floor – Buy Now?

MTD: Mettler-Toledo International logo
MTD
Mettler-Toledo International

Mettler-Toledo International (MTD) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($989.81 – $1,094.01), levels from which it has bounced meaningfully before. Since it first started trading, Mettler-Toledo International stock received buying interest at this level 4 times and subsequently went on to generate 47.3% in average peak returns.

  Peak Return Days to Peak Return
9/1/2020 30.0% 141
3/5/2021 60.5% 300
10/25/2023 56.9% 204
4/9/2025 41.9% 230

Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for MTD?

Rebound likely on strong fundamentals and sector tailwinds.

MTD’s Q1 2026 adjusted EPS of $8.91 and revenue of $947.1M surpassed expectations, with management raising full-year EPS guidance. Despite an immediate 15% stock drop linked to macro jitters, analysts maintain “Buy” ratings and median price targets around $1,445, implying significant upside from current lows. The life science tools market projects robust 6.9-13.8% CAGR through 2026-2031, driven by R&D investment and automation. While tariffs compress margins and debt is notable, strong China growth and product inspection business offer resilience.

Relevant Articles
  1. Figma’s Earnings Just Flipped the Narrative
  2. The Path to $160: The Upside Case for Walmart
  3. POET Stock Doubled In Days. Can The Rally Last?
  4. Is AVGO Stock Expensive At $440?
  5. How Microsoft Stock Rises 50% To $600
  6. Is The Power Grid Now Nvidia’s Biggest Growth Constraint?

How Do MTD Financials Look Right Now?

  • Revenue Growth: 6.8% LTM and 1.3% last 3-year average.
  • Cash Generation: Nearly 19.4% free cash flow margin and 27.5% operating margin LTM.
  • Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for MTD was -4.2%.
  • Valuation: MTD stock trades at a PE multiple of 24.2

  MTD S&P Median
Sector Health Care
Industry Life Sciences Tools & Services
PE Ratio 24.2 23.4

   
LTM* Revenue Growth 6.8% 7.4%
3Y Average Annual Revenue Growth 1.3% 5.7%
Min Annual Revenue Growth Last 3Y -4.2% 0.8%

   
LTM* Operating Margin 27.5% 18.4%
3Y Average Operating Margin 28.2% 18.3%
LTM* Free Cash Flow Margin 19.4% 14.4%

*LTM: Last Twelve Months | For more details on MTD fundamentals, read Buy or Sell MTD Stock.

Trefis: MTD Stock Insights

And What If The Support Breaks?

This stock isn’t immune to big drops. It fell 61% in the Global Financial Crisis and 43% during the Inflation Shock. The Dot-Com Bubble wiped out about 32%, with Covid and 2018 corrections both pushing declines over 25%. Even with strong fundamentals, these dips show the risk. When the market turns south, pullbacks can be steep no matter what.

Still not sure about MTD stock? Consider the portfolio approach.

Portfolios Are The Smarter Way To Invest

Individual stocks can soar or tank, but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside, and mitigate the downside associated with any individual stock.

Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.